Sutro Biopharma, Inc. (STRO): Price and Financial Metrics
STRO Price/Volume Stats
| Current price | $4.50 | 52-week high | $6.13 |
| Prev. close | $4.45 | 52-week low | $2.01 |
| Day low | $4.31 | Volume | 1,940,800 |
| Day high | $4.80 | Avg. volume | 858,034 |
| 50-day MA | $4.04 | Dividend yield | N/A |
| 200-day MA | $4.06 | Market Cap | 368.07M |
STRO Stock Price Chart Interactive Chart >
Sutro Biopharma, Inc. (STRO) Company Bio
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.
Latest STRO News From Around the Web
Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift TooSutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 48% after a shaky period... |
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor |
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination – – Luvelta was generally well-tolerated – – Data supports potential further development in CBF/GLIS AML – SOUTH SAN FRANCISCO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and nove |
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology SummitSOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 2:30 p.m. ET / 11:30 a.m. PT. A webcast of the fireside chat will be accessib |
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 -- SAN CARLOS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc |
STRO Price Returns
| 1-mo | 6.89% |
| 3-mo | 40.63% |
| 6-mo | 26.76% |
| 1-year | 15.09% |
| 3-year | -77.48% |
| 5-year | -59.13% |
| YTD | 4.90% |
| 2023 | -46.91% |
| 2022 | -45.70% |
| 2021 | -31.46% |
| 2020 | 97.36% |
| 2019 | 21.95% |
Continue Researching STRO
Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...